Hydra actinoporin-like toxin-1 (HALT-1) is a 20.8 kDa pore-forming toxin isolated from Hydra magnipapillata. HALT-1 shares structural similarity with actinoporins, a family that is well known for its haemolytic and cytolytic activity. However, the precise pore-forming mechanism of HALT-1 remains an open question since little is known about the specific target binding for HALT-1. For this reason, a comprehensive proteomic analysis was performed using affinity purification and SILAC-based mass spectrometry to identify potential protein-protein interactions between mammalian HeLa cell surface proteins and HALT-1. A total of 4 mammalian proteins was identified, of which only folate receptor alpha was further verified by ELISA. Our preliminary results highlight an alternative-binding mode of HALT-1 to the human plasma membrane. This is the first evidence showing that HALT-1, an actinoporin-like protein, binds to a membrane protein, the folate receptor alpha. This study would advance our understanding of the molecular basis of toxicity of pore-forming toxins and provide new insights in the production of more potent inhibitors for the toxin-membrane receptor interactions.
Introduction
Pore-forming toxins (PFTs) are characterized by their unique ability to form pores in the cell membrane. They are produced by a variety of organisms such as bacteria (Geny and Popoff, 2006) , yeast-fungi (Bussey, 1991) and human (Voskoboinik et al., 2010) . In sea anemones, a group of alpha helical-pore-forming toxins (aPFTs) was isolated and named actinoporins (Ferlan and Lebez, 1974; Kem, 1988; Turk, 1991) . This group of toxins has characteristic features of PFTs, including small protein size of 18e20 kDa, an isoelectric point above 9, lack of cysteine residues and sphingomyelin dependence for membrane binding (Anderluh and Ma cek, 2003; Norton, 2009) . The most studied members of the actinoporin family are equinatoxin II (EqtII) of Actinia equina and sticholysin II (StnII) of Stichodactyla helianthus ( Suput, 2014; Rojko et al., 2016) .
After the first actinoporin was identified in Actinia equina, many other actinoporin-like proteins were identified in other cnidarians. For example, six Hydra actinoporin-like toxins (HALTs) were identified in the genome of Hydra magnipapillata (Glasser et al., 2014) . The amino acid sequences of these toxins share 30% identity with those of actinoporins from sea anemones (Glasser et al., 2014) . In addition, HALT-1 showed haemolytic and cytolytic activity towards red blood cells and HeLa cells (Glasser et al., 2014; Liew et al., 2015) .
HALT-1 has a conserved cluster of aromatic amino acids and an amphiphilic N-terminus, which are proposed to play important roles in membrane binding and pore formation, respectively (Liew et al., 2015) . Although HALT-1 is structurally similar to other actinoporins, a recent study showed that this toxin produced a different pore size from EqtII and did not use sphingomyelin as membrane target (Glasser et al., 2014) . These findings may not be surprising, since HALT-1 and EqtII share only 30% similarity in protein sequence and several amino acid residues known to be involved in sphingomyelin binding in equinatoxin and sticholysin are not conserved in HALT-1 (Liew et al., 2015) .
Although numerous experiments support a critical role for sphingomyelin as the membrane attachment site for sea anemone antinoporins (Bakra c and Anderluh, 2010) , some reports suggested otherwise. For example, De los Ríos et al. (1998) and Caaveiro et al. (2001) tested the lytic action of StnII and EqtII with model membranes having different lipid compositions. Their results showed that these toxins appeared to have the ability to bind to and permeabilize membranes in the absence of sphingomyelin. In fact, EqtII was able to permeabilize large unilamellar vesicles (LUV) containing 30% cholesterol in egg phosphatidylcholine (Caaveiro et al., 2001) as well as LUVs composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glyerol-3-phosphocholine (DPPC) and cholesterol (1:1:1) (Sch€ on et al., 2008) . A similar result was obtained with another actinoporin, sticholysin of Stichodactyla helianthus. This actinoporin was able to permeabilize LUVs composed only of cholesterol and phosphatidylcholine (De los Ríos et al., 1998; Anderluh and Ma cek, 2003; Kristan et al., 2009) . Thus, at least in some in vitro experiments, sphingomyelin is not required for membrane permeabilization by actinoporins.
In the present study, we have searched for alternative membrane receptors, in particular membrane proteins, which could play a role in HALT-1 permeabilization of membranes. The cell membrane is a complex mixture of lipids and proteins and both are functionally important in many cellular processes including as a barrier to separate the interior of the cell from its environment, to selectively transport substances across the membrane and to act as membrane-bound receptors or mediators of signal transduction (Fernandis and Wenk, 2007) . A few bacterial pore-forming toxins have been proven to bind proteinaceous receptors in addition of their affinity to membrane lipids (Dal Peraro and van der Goot, 2016; DuMont and Torres, 2014) . These pore-forming toxins include the intermedilysin (ILY) of Streptococcus intermedius which recognises CD59, an GPI-anchored protein, as the membrane receptor although it has been classified as a cholesterol-dependent cytolysin (Giddings et al., 2004) . Hence, membrane proteins can be potential candidates as receptors for HALT-1.
Since the attempt to show sphingomyelin as an important membrane target site for HALT-1 was not successful (Glasser et al., 2014) and there has been no information on membrane protein binding, we used a combination of GST affinity purification and SILAC based quantitative mass spectrometry to identify potential membrane proteins that bind to HALT-1. This combination offered a powerful approach to identify complexes associated with signalling mechanisms (Ong and Mann, 2006) , including those involving low abundant proteins and weak protein interactions (Bauer and Kuster, 2003) . Using this approach we have identified a membrane protein, which appears to have a role in the binding of HALT-1 to membranes.
Materials and methods

Plasmid construction
For the construction of glutathione-S-transferase-tagged (GSTtagged) at N-terminus of HALT-1 fusion protein, the Gateway cloning system (Invitrogen-Life Technologies, USA) was performed according to the manufacturer's instruction. Prior to the gene cloning, HALT-1 was amplified from HALT-1-pCR4-TOPO using Phusion ® High Fidelity DNA Polymerase (New England BioLabs, USA) and a pair of primers (forward primer 5 0 -CACCGCCAGTG-GAGCAGCTTTAG-3 0 and reverse primer 5 0 -TTATCCAGAAAAAA-TAACTTTGAACTCAGCATGG-3 0 ). The amplicon was then cloned into pENTR™/D-TOPO ® Entry Vector using Directional TOPO cloning system to generate the Entry clone, and followed by the transformation into One Shot ® TOP10 competent cells. To produce the expression vector containing GST-tagged at the N-terminus of HALT-1, the HALT-1 Entry clone was sub-cloned into pDEST™15 Destination vector using LR recombination reaction system and then transformed into Library Efficiency ® DH5a cells. The construct of recombinant GST-tagged HALT-1 was finally verified by sequencing.
Protein expression and purification
The recombinant GST-tagged HALT-1 was expressed in BL21-AI™ One Shot ® E. coli with L-(þ)-arabinose induction (0.2%) for 4 h at 30 C. After the expression, the cells were harvested by centrifugation at 10,000Âg for 5 min. Subsequently, the arabinoseinduced culture was re-suspended in equilibration buffer (50 mM Tris.HCl, 150 mM NaCl, pH 8.0) with additional protease inhibitor PMSF (0.1 mM), and the cells were lysed by sonication at 500 W and 20 kHz. The lysate was centrifuged 2,200Âg for 15 min. For protein purification, a total of 50e200 mg soluble fraction of cell lysate were subjected to affinity chromatography of glutathione agarose (Thermo Fisher Scientific, USA). Purified GST-tagged HALT-1 fusion protein was concentrated and exchanged buffer with BupH Tris buffer using Amicon ® Ultra-2 (Merck Millipore, USA). As based on the manufacturer's protocol of Quick Start Bradford Assay (Bio-Rad, USA), the final concentration of purified GST-tagged HALT-1 protein was measured as 10.8 mg/mL.
Cell culture and SILAC labelling
HeLa cells (ATCC ® CCL-2™) were routinely maintained in Dulbecco's modified Eagle's medium (Gibco/Invitrogen-Life Technologies, USA) supplemented with 10% dialyzed fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 C in 5% CO 2 atmosphere. For SILAC labelling, the incorporation of "light" and "heavy" amino acids into cells was carried out using SILAC Protein Identification (ID) and Quantitation Kits (Gibco/Invitrogen-Life Technologies, USA) according to the manufacturer's instruction. Two sets of HeLa cells were grown separately in two different custom-made SILAC media, in which one group of cells was grown in normal or "light" medium containing 100 mg/mL of L-lysine HCl and 100 mg/ mL of L-Arginine and the other group of cells was grown in labelling or "heavy" medium containing 100 mg/mL of [U-13 C 6 ]-L-Lysine HCl (*Lys) and 100 mg/mL of L-Arginine. Both "light" and "heavy" media were supplemented with 4500 mg/L of glucose, 292 mg/L of Lglutamine, 110 mg/L of sodium pyruvate, 15 mg/mL of phenol red, 1% of penicillin-streptomycin and 10% dialyzed FBS. "Light" and "heavy" labelled cell populations were passaged for at least 9 doubling times to achieve complete incorporation of [U-13 C 6 ]-LLysine HCl (*Lys) (Ong et al., 2002 (Ong et al., , 2003 Ong and Mann, 2006) . Both cell cultures were grown at 37 C in a humidified incubator of 5% CO 2 atmosphere. After cell adaptation, the efficiency of SILAC incorporation into the culture was determined to be >95% by mass spectrometry analysis. The percentage of SILAC incorporation was calculated manually using the following equation: (Oeljeklaus et al., 2014) .
Preparation of cell lysates
For sample preparation, both "light" and "heavy" labelled HeLa cell populations were separately grown to approximately 90% confluence in their respective SILAC media as described above. After that, the medium was removed and cells were washed with 0.9% sterile NaCl, scrapped in 0.9% sterile NaCl and centrifuged at 200Âg for 5 min at 4 C. Whole cell extracts were prepared by dissolving cells in Pierce IP lysis buffer (Thermo Fisher Scientific, USA) (25 mM Tris.HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA and 5% glycerol) with addition Halt™ Protease Inhibitor Single-Use Cocktail (Thermo Fisher Scientific, USA). Two cell suspensions were incubated for 7 min on ice with maximum agitation and subsequently pelleted with centrifugation at 13,000Âg for 10 min at 4 C. Supernatants of "light" and "heavy" labelled cell suspensions were ready for the GST affinity purification.
Affinity purification of GST-tagged HALT-1 binding proteins
To identify HALT-1 binding proteins in cell lysates we used a recombinant GST-HALT-1 fusion protein bound to glutathione agarose beads. Briefly, a total of 12 mg HeLa lysate from SILAC "heavy" medium was incubated with the GST-tagged HALT-1 protein (300 mg) immobilized on agarose beads for 30 min at 4 C. After washing nonspecific proteins from the column, the SILAC-labelled HeLa proteins that bound to HALT-1 were eluted with 2 mL of elution buffer (50 mM Tris.HCl, 150 mM NaCl, 10 mM reduced glutathione, pH 3.0). As a control for non-specific binding, an equal protein amount (12 mg) of HeLa lysate from the SILAC "light" medium was incubated with glutathione agarose beads only, followed by washing and elution. To replicate the experiment, the entire procedure was repeated with the "heavy" and "light" SILAC labels reversed. The HeLa cell lysate from "light" medium was incubated with the GST-HALT-1 fusion protein immobilized on glutathione agarose beads, whereas the HeLa cell lysate from "heavy" medium was incubated with glutathione agarose beads alone.
Equal amount of eluted proteins from "heavy" and "light" cell lysates were analysed in 12% sodium dodedyl suphatepolyacrylamide gel electrophoresis (SDS-PAGE) followed by zinc staining and mass spectrometry analyses.
Liquid chromatography-tandem mass spectrometry and data analysis
Pooled proteins obtained from the affinity purification were incorporated into a polyacrylamide gel matrix to form a tube-gel (Lu and Zhu, 2005) and sent to the Protein and Proteomic Centre, National University of Singapore for the liquid chromatographyetandem mass spectrometry (LC-MS/MS). In brief, the polyacrylamide gel was excised and further processed to in-gel reduction, alkylation, trypsin in-gel digestion and sample desalting/ clean up according to the standard in-gel digestion protocol as described previously with minor modifications (Fukada et al., 2004; Lu and Zhu, 2005) . The finely cut gels were washed with 25 mM ammonium bicarbonate (AMBIC) and dehydrated with 100% acetonitrile (ACN). Subsequently, the samples were reduced with 10 mM dithiothreitol (DTT) for 30 min at 60 C, followed by alkylation with 55 mM iodoacetamide (IAA) for 30 min at room temperature in the dark. The gel pieces were then washed with 25 mM AMBIC, dehydrated with ACN and dried using vacuum centrifuge. After that, the samples were incubated overnight at 37 C with 10 ng/mL trypsin in 25 mM AMBIC for proteolytic digestion of proteins. On the following day, the peptides were extracted from the gel using 50 mL of 25 mM AMBIC, 100 mL of 0.02% heptafluorobutyric acid (HFBA) in deionised water, 150 mL of 0.02% HFBA in 50% ACN and 50 mL of 100% ACN. Hence, four different supernatant fractions from the peptides extraction steps were subsequently pooled together, lyophilized using vacuum centrifuge and desalted prior subjected to LC-MS/MS. Separation of peptides from tryptic peptide mixture was carried out using Eksigent Nanoliquid chromatography (AB SCIEX, USA) for 100 min, followed by the MS analysis using Triple TOF 5600 system (AB SCIEX, USA). To identify the proteins, the mass spectra acquired from the mass spectrometry were searched against the human and decoy (reversed) databases using a Paragon™ Algorithm (Shilov et al., 2007) , ProteinPilot software package version 4.5 (AB SCIEX, USA). The target-decoy approach was set at 5% of false discovery rate (FDR) (Choi and Nesvizhskii, 2008; Elias and Gygi, 2010) .
Statistical data analysis
The data files acquired from LC-MS/MS were viewed and further processed with ProteinPilot version 4.5 software. Here, the data were normalized using global median normalization that shifted the centre of the distribution to zero without affecting the spread. For protein identification and quantitation, only proteins with minimum of 2 unique peptides and proteins that were identified in the experimental replicates with 95% confidence were considered as the candidate protein interactors. In addition, the fold-change approach (SILAC (H/L) ! 2.0 fold) was applied to identify protein interaction partners and hence, identified proteins with low foldchange value from the threshold were discarded. The protein SILAC ratio and its intensity values were inverted for the "reversed" experiment mentioned in 2.5 of this section.
For statistical analysis, Student's t-test (paired sample) followed by the multiple testing Benjamini-Hochberg correction was used to obtain the statistical significance value (p-value < 0.05) (Benjamini and Hochberg, 1995) , using the Statistical Package for the Social Sciences (SPSS) software, version 23.
Bioinformatics analysis
The information of subcellular localization, molecular function and biological process of the identified proteins were obtained from Gene Ontology (GO) (http://geneontology.org) (Ashburner et al., 2000; The Gene Ontology Consortium, 2015) and UniProt (http://www.uniprot.org) (The UniProt Consortium, 2017).
Enzyme linked immunosorbent assay (ELISA)
19.69 nM of human recombinant folate receptor alpha (FOLR-1, Sigma-Aldrich, USA) was immobilized on the immunoplate (SPL 96-well immunoplate, SPL Sciences Co., Ltd., Korea) overnight at 4 C. On the next day, the wells were emptied and washed 3 times with 150 mL of PBST buffer (PBS with 0.2% of Tween-20) for 5 min each. The unoccupied protein-binding sites in wells were blocked by adding 200 mL of 1% BSA in PBS buffer (pH 7.4) and further incubation at room temperature for 2 h. After a routine washing process, 100 mL of 40, 80, 160, 320 and 400 nM) were added to the wells and incubated for 2 h at room temperature. The wells were rinsed three times with PBST buffer before incubating with 100 mL of rabbit a-HALT-1 antibody (1:2000). Then, 100 mL of goat a-rabbit IgG-AP (1:8000) (Santa Cruz Biotechnology, USA) were added and incubated at room temperature for 2 h. After three rinses, 50 mL of substrate 4-MUP (4-methylumbelliferyl-phosphate, Sigma-Aldrich, USA) was added to each well to develop the fluorescent signal. Measurement of the fluorescent signal (excitation/ emission at 355/460 nm) was performed by a multi-mode microplate reader (BMG Labtech, Germany). The intra-assay variability was calculated from the average of triplicate wells in one microplate.
Results and discussion
Identification of potential HALT-1 interaction partners
To identify HALT-1-interacting proteins that could mediate HALT-1 membrane binding, we performed a comprehensive proteomic analysis using SILAC-based quantitative affinity purification and mass spectrometry (SILAC-based q-AP-MS). The schematic workflow of this experiment is presented in Fig. 1 including SILAC labelling, affinity purification (by GST pull-down) and LC-MS/MS. The SILAC procedure was used to distinguish protein(s) binding to HALT-1 from nonspecific proteins binding to the glutathione C 6 ]-L-Lysine HCl) SILAC medium for 9 cell-doubling times. Whole cell lysate was subjected to GST affinity purification of which one column containing "light" labelled cell lysate with GST resin alone and the other column containing "heavy" labelled cell lysate with GST resin conjugated to GST-tagged (N-terminus) HALT-1. After washing, the bound proteins were independently eluted from both columns and then mixed equally before subjected to tube-gel digestion and LC-MS/ MS based analysis. A low "light" MS ion peak together with an at least 2.0-fold higher "heavy" MS ion peak indicates as the putative protein interactor for HALT-1. For the second experiment, the procedure was performed in the same manner as described above except that the "light" labelled cell lysate and the "heavy" labelled cell lysate were reversed in the GST affinity purification. matrix. We first tested the efficiency of SILAC incorporation in HeLa cells after 9 doubling times in SILAC media and its influence on the accuracy and reliability of quantitative mass spectrometry. For this experiment, only heavy labelled HeLa cells were prepared and subsequently processed for protein quantification by LC-MS/MS. The result showed a SILAC-labelling efficiency of 97.33% in HeLa cells, indicating that nearly all peptides or proteins were labelled with SILAC lysine residue ( Supplementary Fig. S1 ). This level of SILAC labelling in HeLa cells was considered satisfactory, since it fell within the range (95e97%) reported in other SILAC labelling experiments (Zhu et al., 2002; Waanders et al., 2007) .
To identify potential HALT-1 interacting proteins a "heavy" cell lysate was added to a column containing GST-tagged HALT-1 immobilized on glutathione agarose beads while a "light" cell lysate was added to a column containing only glutathione agarose beads. In a second experiment, the labels were reversed: the "light" cell lysate was added to GST-tagged HALT-1 immobilized on glutathione agarose beads and the "heavy" cell lysate was added to the column containing glutathione agarose alone. Two pools of proteins collected separately from the eluate fractions of two individual experiments described above were examined by 12% SDS-PAGE gel electrophoresis under reducing condition and then visualized by zinc stain (Supplementary Fig. S2 ) before they were combined for LC-MS/MS analysis. Data of LC-MS/MS were analysed a Accession number is the unique identifier assigned to the entire sequence record when the record is submitted to GenBank. b Ratio of signal intensities of "heavy" and "light" sample pair are calculated by ProteinPilot with default setting to determine the relative level of protein in the two samples.
It is calculated with the weighted average of log ratio of individual peptides belonging to the same protein after background subtraction. c The number of distinct peptides that match to a single protein when MS/MS spectra is searched against a sequence database.
against the human and decoy (reversed sequences) database using Paragom™ Algorithm, ProteinPilot software package (version 4.5, AB SCIEX, USA). In brief, a total of 2458 and 1752 tandem mass spectra were generated from the two experimental replicates, respectively. Subsequently these two numbers resulted in 105 and 117 unique proteins. By using ProteinPilot, we normalized the mass spectrometry data result with global median normalization with aims to minimize the variation between the two data sets.
Subsequently, we carried out the quantitation analysis for each peptide and removed proteins which did not have at least 2 unique peptide hits at 5% FDR (False Discovery Rate). As a result, lists comprising of 41 and 32 protein hits were generated and compiled in Tables 1 and 2 , respectively. Instead of a direct calculation of "heavy" (H) over "light" (L) ratio, ProteinPilot used correction algorithm to measure the percentage error due to various experimental bias. These proteins varied in their SILAC (H/L) ratios and a Accession number is the unique identifier assigned to the entire sequence record when the record is submitted to GenBank. b Ratio of signal intensities of "heavy" and "light" sample pair are calculated by ProteinPilot with default setting to determine the relative level of protein in the two samples.
It is calculated with the weighted average of log ratio of individual peptides belonging to the same protein after background subtraction. The values of ratio H/L are inverted to keep consistency with the values presented in Table 1 . c The number of distinct peptides that match to a single protein when MS/MS spectra is searched against a sequence database. a Accession number is the unique identifier assigned to the entire sequence record when the record is submitted to GenBank. b The statistical significant value shall be p-value < 0.05. were localized in various subcellular compartments as determined by the Gene Ontology.
To further strengthen the selection of interaction partners for HALT-1, only proteins with SILAC (H/L) ratios !2.0 with significant confidence level at 95% (p-value < 0.05) were considered as possible interaction partners for HALT-1. These putative interaction partners of HALT-1 have to be present in both Tables 1 and 2 , and they include 60S ribosomal protein L12, 60S acidic ribosomal protein P2, folate receptor alpha and nucleolin (Table 3) . Fig. 2 demonstrated that the intensities of "light" and "heavy" labelled peptides differ by at least 2.0 fold in the MS/MS spectra for each putative HALT-1 interactor (Fig. 2) . Of the four putative HALT-1 interactors, we eliminated nucleolin, 60S ribosomal protein L12, and 60S acidic ribosomal protein P2 as nonspecific binding partners, since they are abundant intracellular proteins and are known to interact with affinity matrices such as sepharose (Gingras et al., 2007; Trinkle-Mulcahy et al., 2008) . Furthermore, they are commonly detected protein contaminants in q-AP-MS experiments . Therefore, we focused our attention on one candidate, folate receptor alpha, which gave a strong H/L signal in both experiments and is located on the cell membrane and thus a potential target for HALT-1.
Verification of folate receptor alpha binding to HALT-1
To verify the interaction between HALT-1 and folate receptor alpha, we performed an ELISA binding assay with various HALT-1 concentrations to folate receptor alpha that was coated on the well surface of immunoplate. Fig. 3 shows that HALT-1 bound to folate receptor alpha in a dose-dependent manner ranging from 0 to 400 nM (or 0e10 mg/mL). The intensity of signal has not reached a plateau because the amount of HALT-1 has yet to saturate the coated FOLR1 but the antibodies used was enough to give a discernible detection signal at the highest concentration of HALT-1. Controls lacking either folate receptor alpha, HALT-1, anti-HALT-1 antibody or secondary antibody resulted in very low or insignificant signals. Therefore, there was a direct, in vitro binding of HALT-1 to folate receptor alpha suggesting a possible involvement of folate receptor alpha in the mechanism of HALT-1 induced cell lysis.
Concluding remarks
The folate receptor alpha is a GPI-anchored (glycosylphosphatidylinositol-anchored) membrane protein of 38e 40 kDa that plays a major role in the uptake of folate/folic acid into cells via endocytosis (Luhrs and Slomiany, 1989; Basal et al., 2009) . Folate receptor alpha is attached to the GPI anchor via its C-terminal end (Paulick and Bertozzi, 2008; Maeda and Kinoshita, 2011) . Therefore, the folate receptor alpha is localized on the outer surface of the cell membrane and could serve as the membrane attachment site for extracellular proteins, possibly including HALT-1. This hypothesis is supported by the fact that the alpha-toxin of Clostridium septicum binds to the GPI-anchored form of folate receptor alpha (Gordon et al., 1999) before it is cleaved approximately 4 kDa from the C-terminus to become an active cytolysin (Melton-Witt et al., 2006) . Similarly, we suggest that folate receptor alpha could serve as a membrane receptor for HALT-1 instead of the lipid sphingomyelin, which has been previously thought to be the solely attachment site for HALT-1 on the cell membrane (Liew et al., 2015) . This idea is supported by the results of Glasser et al. (2014) who pointed out the likelihood of an alternative binding site for HALT-1. In brief, these authors compared the binding affinity of sphingomyelin to HALT-1 and EqtII in a haemolysis assay. Their results clearly showed that the concentration of sphingomyelin that fully inhibited the haemolytic activity of EqtII failed to block the haemolytic activity of HALT-1. Thus, the binding affinity of HALT-1 to sphingomyelin is at least 100-fold weaker than that of EqtII. HALT-1 also lacks conserved amino acids in the sphingomyelin binding site.
We cannot totally rule out the possibility that HALT-1 binds to more than one attachment sites on cell membrane since some bacterial pore-forming toxins are able to bind more than one membrane receptors. A good example is the intermedilysin (ILY) of Streptococcus intermedius which recognises CD59, an GPI-anchored protein, as the membrane receptor although it has been classified as a cholesterol-dependent cytolysin (Giddings et al., 2004) . a-hemolysin of Staphylococcus aureus is another example of PFTs binding to multiple membrane target sites. a-hemolysin has been known to have a low affinity to phosphocholine head groups but it was later proven to interact with ADAM10 (a disintegrin and metalloprotease 10) which is a transmembrane protease present in wide variety of cells (Valeva et al., 2006; Wilke and Wardenburg, 2010) .
In summary, by a combination of affinity purification and SILACbased quantitative mass spectrometry we have identified the folate receptor alpha as an interaction partner of HALT-1. This result provides an alternative to the previously established binding of HALT-1 to the lipid sphingomyelin. By identifying the potential membrane receptors for HALT-1, we have unravelled the essential step in the lytic mechanism by Hydra's toxin. The next step is to gain a deeper understanding of the possible role of folate receptor alpha in pore formation. This is particularly crucial to understand how the initial toxin-membrane receptor interaction leads to the subsequent adverse effects or illness in host body. The findings of this study also provided a broad implication for making anti-PFTs therapies that aims to disrupt the toxin-membrane receptor interactions. For most toxins, their interactions with membrane receptors are highly specific and hence the therapies can target these specific interactions and leave other receptor sites unharmed. 
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